| Variable | No. (%) |
|---|---|
| Treatment efficacy | |
| CD4 count / µL (mean ± SD) | 265 ± 198 |
| PVL (log10) (mean ± SD) | 1.9 ± 0.6 |
| Undetectable (pVL ≤ 2.0 log10) | 87 (86.1) |
| Favorable response | 55 (54.5) |
| Failure | 14 (13.9) |
| Virological / immunological dissociation | 32 (31.7) |
| Adverse events | |
| IRD | 11 (10.9) |
| Severe heptotoxicity | 2 (1.9) |
| Lipodystophy | 31 (30.6) |
| Hyperlipidemia | 58 (57.4) |